BEDFORD, Mass., Sept. 30, 2014 /PRNewswire/ -- Hologic, Inc.
(NASDAQ: HOLX), today announced that Stephen MacMillan, Hologic's President and Chief
Executive Officer, will preside over the NASDAQ Stock Market
Opening Bell Ceremony on October 1,
the first day of Breast Cancer Awareness Month. In his remarks, Mr.
MacMillan will discuss the Company's campaign focused on the
important benefits of Hologic's 3D Mammography technology, the only
3D system approved by the FDA as clinically superior to traditional
mammography.
This is the ninth consecutive year that Hologic has been
invited to participate in the NASDAQ Opening Bell Ceremony on the
first business day in October.
"It is an honor to host the NASDAQ Opening Bell Ceremony on the
first day of Breast Cancer Awareness Month," said Mr. MacMillan.
"We are committed to developing technologies that detect diseases
earlier and improve patient outcomes. Our 3D mammography technology
is truly revolutionary. It addresses the limitations of traditional
mammography – the over-diagnosis of non-invasive cancers and
unnecessary recalls for additional testing – with the demonstrated
ability to increase the detection rate of invasive cancers. It is
the first and only 3D system that is clinically proven to be
superior to traditional 2D mammography. Throughout October, we will
focus on encouraging women to become their own advocates, by taking
control of their health and learning more about this game-changing
technology. Hologic's 3D Mammography is an important new tool in
the treatment of breast cancer that empowers doctors to have
greater confidence in their diagnoses and patients to have greater
confidence in the results."
Hologic's 3D Mammography Technology:
Hologic was the first company to receive FDA approval for its 3D
mammography system. This technology was approved for breast cancer
screening and diagnosis in the U.S. in February 2011 and has been available in countries
recognizing the CE mark since 2008. Hologic offers a comprehensive
3D platform including low-dose 3D mammography, as well as the first
FDA approved 3D-guided breast biopsy system.
Hologic's groundbreaking 3D mammography exam is the only one
approved as clinically superior to traditional mammography by the
FDA. Unlike conventional 2D mammography where the presence of
overlapping breast tissue can make it more difficult to detect
cancer, Hologic's 3D technology is designed to allow doctors to see
the breast more clearly for all women. As a result, fewer
women are called back for additional testing due to false positive
results. Since 2011, over 8 million women in the U.S. have
benefited from Hologic's 3D Mammography.
Hologic's 3D Mammography technology is in use in all 50 states
and more than 50 countries. Additional information, as well as
Hologic's 3D site finder, can be found at
www.3DMammography.com.
Webcast Information:
The Hologic NASDAQ Stock Market Opening Bell Ceremony will be
aired live at https://new.livestream.com/nasdaq/live (access
this by clicking on the MarketSite live webcam) and will also be
aired with closed captioning on the NASDAQ MarketSite Tower in
Times Square. A video of the Opening Bell ceremony will be archived
for one year on the NASDAQ site.
About Hologic, Inc.:
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal health. With
a unified suite of technologies and a robust research and
development program, Hologic is dedicated to The Science of Sure.
For more information on Hologic, visit www.hologic.com.
Hologic, 3D Mammography, and associated logos are trademarks
and/or registered trademarks of Hologic, Inc. and/or its
subsidiaries in the United States and/or other
countries.
Forward-looking Statement Disclaimer:
This News Release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic 3D Mammography systems. There can be no assurance
the systems will achieve the benefits described herein and that
such benefits will be replicated in any particular manner with
respect to an individual patient as the actual effect of the use of
the systems can only be determined on a case-by-case basis
depending on the particular circumstances and patient in question.
Hologic expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to the statements
presented herein to reflect any change in the Company's
expectations or any change in events, conditions or circumstances
on which any such statements are based.
Contacts:
|
|
|
|
Investors
|
Media
|
Deborah
Gordon
|
Jim Culley
|
Vice President,
Investor Relations
&
|
Senior Director,
Corporate Communications
|
Corporate
Communications
|
|
(781)
999-7716
|
(302)
528-1312
|
deborah.gordon@hologic.com
|
jim.culley@hologic.com
|
|
|
|
Marianne
McMorrow
|
|
Manager, Corporate
Communications
|
|
(781)
999-7723
|
|
marianne.mcmorrow@hologic.com
|
SOURCE Hologic, Inc.